eleva GmbH
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Multiple Therapeutics
Eleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biological therapeutics. Eleva’s disruptive moss-based technology platform enables GMP-scale manufacturing of human proteins with tremendous therapeutic potential that have been too challenging to manufacture using other approaches. The company’s proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. The lead program, CPV-104 recombinant human complement Factor H, is in Phase 1b testing to treat C3 Glomerulopathy (C3G). An intravitreal formulation of the candidate is in late preclinical development to treat dry AMD. The company’s aGal (RPV-001) program has completed a positive Phase 1b single-dose clinical trial to treat Fabry disease.
Company HQ City:
Freiburg
Company HQ State:
Baden-Wuerttemberg
Company HQ Country:
Germany
Year Founded:
1999
Lead Product in Development:
Factor H (CPV-104)
CEO
Björn Cochlovius, PhD
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
Q3/2026
What is your next catalyst (value inflection) update?
Top Line Results Phase I Factor H (CPV-104) in C3G
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}